Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.

You may also be interested in...



GAO Tracks Decline In ESA Use Following Regulatory Changes

A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.

ESRD Market Snapshot: The Price Has To Be Right

The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.

Amgen Hits Another Emerging Market Target With $700M Turkish Deal

Fulfilling its pledge to dramatically expand internationally, Amgen sealed a deal to purchase coveted drugmaker Mustafa Nevzat, gaining a foothold in Turkey. Meanwhile, its pipeline progresses with no clear winners to help cushion the blows to the company’s ESAs.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel